
    
      The investigators enrolled 441 NPC patients who had finished finished curative radiotherapy
      with/without chemotherapy and no recurrence/metastasis before entry this study from five
      hospitals in Taiwan. Blood samples were collected on the day of enrollment and monitored once
      every 2-3 months for plasma EBV DNA measurement. After long-term observation, we analyze the
      impact of continuous plasma EBV DNA monitoring on the early dection of tumor relapse and do
      risk grouping for survival analyses according to the blood test results.
    
  